Our Purpose

Serving Science

We are focused on providing premium quality products and a superior cell culture experience for our customers. We understand how important cell culture is to the success of life science research. These cells are what enable the scientific breakthroughs that extend and save lives. Your ability to generate quality data is dependent upon using tested, proven products.

A trusted source for precision cell culture solutions that feed scientific breakthrough.

Curing disease starts with science

In a perfect world, all scientific experiments move forward without confounding variables. While perfection isn’t possible, mitigating risk by demanding only the highest quality cell culture products will facilitate scientific breakthroughs. Working together, we can speed up discovery and cure disease by ensuring that our products meet the demanding requirements of those fueling today’s increasingly complex scientific innovations.

At the core of cell science

We are elevating consistency and authenticity in cell culture. We believe we can accomplish this by delivering superior products through a transparent, consistent and proven supply chain that eliminates variability for you, our customers.

“For us to realize our mission of speeding the time from discovery to cure we must be unrelenting in the pursuit of innovation of product and process.”

– Chief Executive Officer, David Sheehan

Leadership Team

David Sheehan

David Sheehan

President, CEO, Director

Dave has 25 plus years in the life science industry.   Dave was previously at Volcano Corporation a $1.2 Billion, publicly held, life sciences company that was sold to Philips. Dave held various roles including the COO, EVP Global Operations and General Manager Volcano Japan, and President of several business units.  Prior to Volcano, Dave was the President and CEO of Digirad a medical imaging company he took public in 2004.  Prior to that, Dave worked at Baxter and Haemonetics.  He has extensive experience in life sciences, product development, manufacturing, international markets, acquisitions and integrations, and organization development. Dave earned a BSME with Distinction from WPI and an MBA from The Amos Tuck School at Dartmouth College.

Martha Laundroche

Martha Laundroche

CFO

Martha has provided executive level financial and business leadership to a diverse base of companies over the past 25 plus years, spending most of the last 15 in the life sciences industry, including 10 with eMolecules Inc., a world class chemistry search engine and e-commerce platform empowering scientific researchers around the globe to deliver more efficient drug-discovery programs. Martha started her professional career in the Detroit office of Arthur Andersen LLP on the audit and financial litigation consulting staffs after earning her BBA with Highest Distinction in Professional Accounting from The University of Michigan. Martha obtained her CPA license in the states of Michigan and California and was a bronze medal recipient of the AICPA Elijah Watts Sells Award.
David Sheehan

Dr. Bernie Huyghe

VP of Manufacturing

Bernie has been in biologics manufacturing for the last 30 years. He spent the last 11 years at Pfizer working in a variety of manufacturing and process development roles. He was part of the allogenic CAR T program at Pfizer and helped transition the manufacturing process to Allogene. Prior to that he spent time in a variety of manufacturing roles at Chugai and CovX which was acquired by Pfizer. He has PhD in Physical Biochemistry from U of California Berkeley.

Dr. Alyssa Master

VP of Quality and Customer Experience

Dr. Alyssa Master has ten years of laboratory research experience including five years as a lab manager prior to joining Nucleus Biologics. As a biomaterials engineer, her area of expertise is in the field of nanoparticle-mediated drug delivery, particularly for the delivery of cancer therapeutics. In graduate school, Alyssa was the recipient of both the Medtronic Fellowship and the NIH Ruth L. Kirschstein Predoctoral Fellowship. During these fellowships, Alyssa developed a novel targeted drug delivery platform for intravenous delivery of photodynamic therapy agents. Following graduate school, Alyssa completed a postdoctoral fellowship in the Department of Pharmacology at the University of Illinois at Chicago Medical School and a postdoctoral fellowship in the Division of Molecular Pharmaceutics at the University of North Carolina at Chapel Hill School of Pharmacy. Alyssa has a PhD in Biomedical Engineering from Case Western Reserve University.

Francisco Martinez-Becerra

Dr. Francisco Martinez-Becerra

Head of Research

Dr. Francisco Martinez-Becerra has over 20 years of experience in the fields of immunology, vaccinology, and cell culture. In his past role as the Director of the Immunology Core Lab of the Kansas Vaccine Institute at the University of Kansas, Francisco worked developing protocols for high throughput assays to measure cellular and humoral immune responses in a variety of fields such as multiple sclerosis, influenza and HIV. As a Research Assistant Professor, Francisco led the development of subunit vaccines against Shigella, Salmonella, Yersinia, and Bordetella. Francisco earned a bachelor’s in Biomedical Research and a PhD in Immunology from the National Autonomous University of Mexico. He held postdoctoral positions at the School of Medicine, National Autonomous University of Mexico; the Center for Vaccine Development, University of Maryland; and Oklahoma State University.

Rachel Gauvin

Rachel Gauvin

Head of Program Management

Rachel has over 10 years of experience in project and program management.  A Lean Management Certified manager, Rachel has managed cross functional teams in everything from implementing complex research projects to business process mapping and employee training.  She is comfortable building accountability in organizations ranging in size from federal contracting agencies to start-ups.  Rachel has a B.A. in Psychology with a minor in Bioethics from Michigan State University and a Master’s in Public Health from the University of Illinois at Chicago.

Tim Schofield

Senior Director of Cell Therapy Solutions

Tim Schofield has 20 years of sales and marketing experience in molecular diagnostics, life sciences and pharmaceuticals. Tim began his career as a sales representative with Johnson & Johnson and held positions of increasing responsibility at Prometheus Laboratories, bioTheranostics and NanoString Technologies. Tim has launched over twenty products in both US and Global markets during his career. He has extensive experience in immuno-oncology, oncology, and immune mediated diseases of inflammation such as Crohn’s Disease and celiac disease. He is on the Advisory Board for Beyond Celiac. Tim received his MBA from the Atkinson Graduate School of Management at Willamette University, a bachelor’s degree in Business Administration from Western Washington University and a proficiency certificate in Japanese from Sophia University in Tokyo.

Board of Directors

Shehan Dissanayake, PhD

Chairman of the Board

Shehan is a senior Managing Director and member of the Board of Directors of the Tavistock Group, a privately held investment company. He has responsibility for portfolio strategy across 200 companies in 15 countries, and is CEO of Tavistock Life Sciences, an operating unit of the Tavistock Group.

Before joining Tavistock Group in 2002, Shehan was a Managing Partner of Arthur Andersen with responsibility for strategy and business planning for the global legal, tax and HR Consulting Divisions of the firm, encompassing 1,600 partners and 15,000 professionals.

He holds a Ph.D. in Pharmacological and Physiological Sciences from The University of Chicago.

Kieran T. Gallahue

Director

Kieran was Chairman of the Board and Chief Executive Officer of CareFusion Corporation from 2011 until March 2015 when it was sold to Becton Dickinson. Previously, Kieran joined ResMed, Inc. in 2003 as President and Chief Operating Officer of the Americas, was promoted to the role of President and Chief Operating Officer of ResMed Global in 2004, and Chief Executive Officer and director in 2008. Kieran also served on the board of Volcano Corporation until 2015. Prior to 2002, he held various marketing, sales and financial positions within Nanogen, Inc., Instrumentation Laboratory, the Procter & Gamble Company, and the General Electric Company. Kieran currently sits on the board of directors of Edwards Lifesciences and Arena Pharmaceuticals. Kieran has a bachelor’s degree from the Rutgers University College of Agricultural and Biological Sciences and an MBA from Harvard Business School.

Suzanne Devkota, PhD

Director

Suzanne is an assistant professor in the Cedars-Sinai Division of Gastroenterology investigating the role of diet in host immune responses and on counteractive nutritional therapies. Devkota teams with Cedars-Sinai physicians to combine clinical and basic research utilizing patient samples, in vivo conventional and gnotobiotic animal models, and sequencing- and culture-based microbial methodologies to investigate the molecular mechanisms underlying clinical phenomena. Her goal is to add a powerful new dimension to diagnosis and treatment through a better understanding of gut microbial contributions to disease.

She holds Master’s degree from University of Illinois, a PhD in Biological Sciences from University of Chicago and post doctoral work at Joslin Diabetes Center at Harvard Medical School.

David Sheehan

President, CEO, Director

Dave has 25 plus years in the life science industry.   Dave was previously at Volcano Corporation a $1.2 Billion, publicly held, life sciences company that was sold to Philips. Dave held various roles including the COO, EVP Global Operations and General Manager Volcano Japan, and President of several business units.  Prior to Volcano, Dave was the President and CEO of Digirad a medical imaging company he took public in 2004.  Prior to that, Dave worked at Baxter and Haemonetics.  He has extensive experience in life sciences, product development, manufacturing, international markets, acquisitions and integrations, and organization development. Dave earned a BSME with Distinction from WPI and an MBA from The Amos Tuck School at Dartmouth College.

Anthony J. Abraham

Director

Mr. Anthony J. Abraham, BEc, LLB (Accountancy and Law) is currently also a Board Director at Australian Agricultural Company Limited. Mr. Abraham previously served as Chief Executive Officer at Macquarie Group. Mr. Abraham enjoyed 21 years in investment banking with the Macquarie Group. Mr. Abraham was involved in agricultural funds management from 2003 within Macquarie until he departed in 2011. Mr. Abraham has a wealth of experience in investment having played an integral role in Macquarie Group’s expansion into Australian agriculture. Mr. Abraham joined Macquarie in 1990 after four years in the tax consulting division of a chartered accounting firm.